Evidence map›Paper›PMID 38507062›Full record

ArticleCancer chemotherapy and pharmacology2024

Pharmacokinetics, mass balance, and metabolism of [

Sheng Ma, Xin Wang, Shu Yan, Liyan Miao, Xiaojing Wan, Dawei Ding, Ding Yu, Xingxing Diao, Xunqiang Wang, Hua Zhang

Abstract readClinical Trial, Phase I
PubMed Publisher
In one paragraph

Article in Cancer chemotherapy and pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Unravelling the human disposition of [British journal of clinical pharmacology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sheng Ma *Department of Pharmacy, The First Affiliated Hospital of Soochow University, Suzhou, China.
Xin Wang *Department of Clinical Research Center, Chia Tai Tianqing Pharmaceutical Group Co., Ltd, Nanjing, China.
Shu Yan *Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Liyan MiaoDepartment of Pharmacy, The First Affiliated Hospital of Soochow University, Suzhou, China.
Xiaojing WanDepartment of Clinical Research Center, Chia Tai Tianqing Pharmaceutical Group Co., Ltd, Nanjing, China.
Dawei DingDepartment of Clinical Research Center, Chia Tai Tianqing Pharmaceutical Group Co., Ltd, Nanjing, China.
Ding YuDepartment of Clinical Research Center, Chia Tai Tianqing Pharmaceutical Group Co., Ltd, Nanjing, China.
Xingxing DiaoShanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Xunqiang WangDepartment of Clinical Research Center, Chia Tai Tianqing Pharmaceutical Group Co., Ltd, Nanjing, China. wxq@cttq.com.
Hua ZhangDepartment of Pharmacy, The First Affiliated Hospital of Soochow University, Suzhou, China. zhanghua_suzhou@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeEnvonalkib (TQ-B3139) is a novel, potent anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor used to treat ALK-positive non-small cell lung cancer. This phase I mass balance study investigated the pharmacokinetics, metabolism, and excretion of

methodsA single oral dose of 600 mg (150 µCi) [

resultsAfter dosing, the median T

conclusionEnvonalkib was extensively metabolized prior to excretion and eliminated primarily as metabolites via feces.

Indexed as

Anaplastic Lymphoma KinaseProtein Kinase InhibitorsAdministration, OralAdultCarbon RadioisotopesEast Asian PeopleFecesHealthy VolunteersHumansMaleMiddle AgedReceptor Protein-Tyrosine KinasesTyrosine Kinase InhibitorsYoung AdultALK protein, humanAnaplastic Lymphoma KinaseCarbon RadioisotopesProtein Kinase InhibitorsReceptor Protein-Tyrosine KinasesTyrosine Kinase InhibitorsEnvonalkibExcretionMass balanceMetabolismPharmacokineticsTQ-B3139

Identifiers

PMID38507062

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.